Could This Safe Play Help Eli Lilly & Co. (LLY)?

Page 1 of 2

At the American Diabetes Association meeting last month, Eli Lilly & Co. (NYSE:LLY) presented promising data for the GLP-1 agonist dulaglutide. GLP-1s are a well-established diabetes drug class dominated by Novo Nordisk A/S (ADR) (NYSE:NVO) and Bristol Myers Squibb Co. (NYSE:BMY).

Eli Lilly & Co. (NYSE:LLY)

GLP-1 agonists are typically used as a second-line combo therapy for type 2 diabetes patients not responding to metformin and insulin. These drugs are generally well-tolerated and carry little risk of hypoglycemia, which makes this class one of the safest diabetes plays.

But how much could this safe play mean for Eli Lilly & Co. (NYSE:LLY)’s overall health?

GLP-1 market

Twice-daily Byetta was the first GLP-1 to market with a Food and Drug Administration approval in 2005. But Victoza quickly took over after its 2010 approval due to a once-weekly dosage.  Victoza has maintained a fairly steady climb ever since. The drug achieved 2012 sales of DKK 9.5 billion (or about $1.6 billion according to current conversion rates), and contributed 39% of the company’s overall sales growth.

Bydureon was brought out last year as a once-weekly version of Byetta. It’s still too early after launch to predict Bydureon’s sales growth, but EvaluatePharma pegged the drug as one of the top five “blockbuster duds” in the past year. Bydureon could see soft sales merely because Victoza got there first and patients don’t want to change treatments.

How does dulaglutide stack up?

Would the once-weekly dulaglutide hold its own in the GLP-1 market — or face a future even less certain than Bydureon’s?

Eli Lilly offered up data from three late-stage trials that showed dulaglutide outperforming Merck’s DPP-4 Januvia, Byetta, and metformin.  Dulaglutide helped patients control blood sugar better than the other drugs and also helped patients lose more weight.

Dulaglutide still has other competitor comparing trials underway. The late-stage trials include Lantus, the company’s own insulin Humalog, and — most importantly — one trial with Victoza. The Victoza trial won’t report until after dulaglutide goes before the FDA for approval later this year. But favorable results could push dulaglutide into a stronger market position.

Other new contenders

Sanofi SA (ADR) (NYSE:SNY)’s Lyxumia received FDA approval in the U.S. and Europe this past February. Lyxumia’s trial results were lackluster and drew criticism for being a Byetta clone. But, as I’ve written previously, Sanofi’s really betting on this drug as a combo therapy for its $7 billion Lantus insulin — a product that loses patent protection in 2015.

Page 1 of 2
Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

The Best B-Boy Movies

Most Awesome Hip Hop Documentaries

Foods That Stain Your Teeth

Richest Doctors in the World

The Best Movie Sountracks Ever

The Highest Grossing Musicals on Broadway

The Most Successful Reality TV Stars

Cheapest Cities to Visit in the US

Most Expensive Summer Camps

Most Expensive Animals in the World

Most Expensive Specialty Crops in the World

Movies That Took Ages to Make

The Longest Hollywood Films Ever Made

Most Expensive Concert Stages

The Richest Bands of all Time

10 Most Corrupt Countries 2013 List

10 Countries with the Highest Quality of Life Index

Most Expensive Mattresses in the World

5 Smallest Countries by Land Area

The Ultimate Heartbreak Songs

Richest Teenagers in the World

10 Most Haunted Places in America

10 Best Places to Retire in Florida East Coast

Top 10 Places to See Before You Die

Top 8 Countries in the World Where Justice Prevails

10 Richest States in America

15 Wealthiest Countries in the World

Richest Singers in the World

Most Expensive Tasting Menu in New York City

Most Expensive Baby Items in the World

Most Expensive Hotel Suites in Vegas

Most Expensive Brunch in New York City

Most Expensive Beef Cuts in the World

25 Best Colleges to Get a Job

Top 10 US Supermarkets

The 25 Most Dangerous Cities in the World to Visit

Most Expensive Xbox Games

Top 11 Cities Where Billionaires Live

Top 10 Most Charitable Companies in America

Most Expensive Seafood in the World

The 10 Wildest Conspiracy Theories

The 10 Best Job Markets in the US

Top 10 Accounting Scandals of All Time

The 25 Biggest Cities in the World

Top 10 Best Paying Virtual Jobs

Most Expensive Leather Shoes in the World

Top 6 Things to Buy in March

The 10 Most Stressful Jobs in America – 2014 List

Top 10 Jobs for Introverted People

Top 10 Honeymoon Destinations in the World

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!